Correlated abnormalities of transforming growth factor-β1 response and p53 expression in thyroid epithelial cell transformation
References (36)
- et al.
J. Biol. Chem.
(1989) - et al.
Exp. Cell Res.
(1986) - et al.
Cell
(1988) - et al.
Cell
(1989) - et al.
Lancet
(1990) - et al.
Cell
(1990) - et al.
Adv. Cancer Res.
(1988) - et al.
Biochem. Biophys. Res. Commun.
(1986) - et al.
Exp. Cell Res.
(1989) - et al.
Mol. Cell. Endocrinol.
(1989)
Exp. Cell Res.
Science
Oncogene
Oncogene
J. Virol.
Carcinogenesis
EMBO J.
Cited by (57)
Efficacy of lentiviral-mediated transfection of hTSHR in poorly differentiated thyroid carcinoma cell line
2013, Nuclear Medicine and BiologyCitation Excerpt :Thyrotropin (TSH) is a thyroid-specific growth factor inducing differentiated function and growth of thyrocytes [12]. In human thyroid cancer cells, TSH stimulates differentiated function and growth by the activation of TSH-dependent adenylate cyclase–protein kinase A pathways, independently of insulin or IGF [13–15]. Investigations in vivo have indicated that in poorly differentiated thyroid cancer, TSHR expression decreased or was even suppressed [4].
Integrative radiation carcinogenesis: Interactions between cell and tissue responses to DNA damage
2005, Seminars in Cancer BiologyTransforming growth factor-β1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells
2000, Journal of Biological ChemistryCitation Excerpt :Resistance to TGF-β1-mediated growth inhibition is a common feature of many malignancies of lymphoid and epithelial origin and may contribute to their aberrant proliferation (60). Analysis of some malignant cells has correlated this insensitivity to TGF-β1 with the expression of mutant forms of p53 (46, 47). This and the demonstration that overexpression of mutant p53 can confer partial resistance to TGF-β1 have suggested that p53 may be involved in TGF-β1 growth-inhibitory pathways (48, 49).